Previous 10 | Next 10 |
home / stock / prax / prax articles
Needham initiated coverage on Praxis Precision Medicines Inc (NASDAQ:PRAX), a clinical-stage biopharmaceutical company, engaged in the development ...
BOSTON, May 17, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating ...
BOSTON, May 10, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating ...
BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translatin...
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translatin...
Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected fourth-quarter...
Praxis Precision Medicines Inc (NASDAQ:PRAX) provided an update on its Phase 2a proof of concept study evaluating PRAX-628 in epilepsy patient...
U.S. stocks were higher, with the Dow Jones index gaining around 50 points on Tuesday. Shares of Tesla Inc (NASDAQ: TSLA) rose sharply during Tuesd...
In the 45 mg cohort, 100% of patients achieved a complete response In the 15 mg cohort, 80% of patients achieved a complete response and 20% achi...
News, Short Squeeze, Breakout and More Instantly...
Praxis Precision Medicines Inc. Company Name:
PRAX Stock Symbol:
NASDAQ Market:
Praxis Precision Medicines Inc. Website:
2024-05-20 14:30:05 ET Piper Sandler analyst issues OVERWEIGHT recommendation for PRAX on May 20, 2024 12:01PM ET. The previous analyst recommendation was Overweight. PRAX was trading at $44.93 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-05-16 16:30:03 ET Jefferies analyst issues BUY recommendation for PRAX on May 16, 2024 02:01PM ET. The previous analyst recommendation was Buy. PRAX was trading at $45.32 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...